Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alvelestat- dose 1 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Placebo Oral Tablet | DRUG | twice daily administration |
| Alvelestat oral tablet - dose 1 | DRUG | twice daily administration |
| Alvelestat oral tablet - dose 2 | DRUG | twice daily administration |
Alvelestat is an investigational small molecule being developed for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic condition, and for Covid-19. It has been studied in clinical trials for AATD-related COPD and emphysema, as well as for Covid-19.
Alvelestat is a small molecule that targets neutrophil elastase, an enzyme involved in tissue destruction in Alpha-1 Antitrypsin Deficiency. By inhibiting this enzyme, it aims to reduce lung damage associated with the condition.
Alvelestat is being developed by Mereo BioPharma Group plc, a biopharmaceutical company listed on the stock exchange under the ticker MREO. The company is focused on rare disease therapeutics.
Alvelestat is in Phase 2 clinical development. It has completed Phase 2 trials for Alpha-1 Antitrypsin Deficiency and a Phase 1 trial for Covid-19. It is not yet approved by the FDA and remains investigational.
Alvelestat has completed three clinical trials: NCT03636347, a Phase 2 study in AATD-related COPD; NCT03679598, a Phase 2 study in AATD; and NCT04539795, a Phase 1 study in Covid-19. All trials are completed.
Yes, Alvelestat is also known as MPH966. Clinical trial records reference both names, with MPH966 appearing in the titles of studies such as NCT03636347.